Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing the impact of future revenue externalizations and asset disposals on revenue and earnings growth. Consensus estimates may overestimate revenue by up to $2.5B and core operating profit by up to $850M by 2021, Holford tells investors in a research note. 2. J.M. Smucker (SJM) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Matthew Grainger saying increased retail competition adds to a challenging US Foods backdrop. The analyst sees two headwinds emerging from Wal-Mart's (WMT) increased leverage over Food manufacturers and renewed private label growth. Grainger said J.M. Smucker's has outsized risk to Wal-Mart and private label risk , and as a result downgraded shares and lowered his price target to $126 from $132. 3. Marriott (MAR) downgraded to Buy from Conviction Buy at Goldman with analyst Stephen Grambling citing outperformance versus the S&P since adding shares to the Conviction Buy List on September 25, 2016. 4. AMC Networks (AMCX) downgraded to Neutral from Overweight at Piper Jaffray with analyst Stan Meyers citing viewership declines at the flagship Walking Dead franchise, "quickly accelerating" content and marketing costs as well as his firm's teen survey which indicated teens are turning away from cable at a faster pace. The analyst cut his price target AMC shares to $60 from $73. 5. Cinemark (CNK) downgraded to Buy from Conviction Buy at Goldman with analyst Michael Ng citing valuation and maintained its Buy rating and $49 price target. The analyst expects Cinemark to outperform box office growth in 2017 given its aggressive rollout of recliners across its US footprint in 2016. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Bearish flow noted in AstraZeneca with 3,362 puts trading, or 1.7x expected. Most active are 4/26 weekly 70 puts and May-24 70 calls, with total volume in those strikes near 3,600 contracts. The Put/Call Ratio is 1.72, while ATM IV is up nearly 2 points on the day. Earnings are expected on April 25th.

Mizuho lowered the firm's price target on Marriott to $260 from $263 and keeps a Neutral rating on the shares. The analyst cites a more conservative view on RevPAR ahead of the Q1 report for the target drop. RevPAR trends have been slightly weaker than previously modeled, primarily in the United States, the analyst tells investors in a research note.